Image Place holder

Michael R. Shafique, MD


Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Dr. Shafique earned his MD degree at the University of Virginia, School of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center and, most recently, a Hematology and Oncology Fellowship at University of South Florida/Moffitt Cancer Center. Dr. Shafique devotes the majority of clinical time treating lung cancer. However, he will also cares for patients with a wide spectrum of diagnoses as part of early phase clinical trials.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of South Florida - Hematology and Oncology

Residency:

  • Duke University Medical Center - Internal Medicine

Medical School:

  • University of Virginia School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19293
Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
Condition:
Intervention: Avelumab; MSB00100718C (Avelumab); VX15/2503
Open

CLINICAL TRIAL 18558
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB00100718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
Condition:
Intervention: Avelumab; MSB00100718C (Avelumab); PD 0360324; PF-04518600; PF-05082566 (utomilumab); utomilumab
Open

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition:
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition:
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition:
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AMP-514 (Durvalumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); CP-675,206 (tremelimumab); Dexamethasone; Durvalumab; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel; tremelimumab
Open

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition:
Intervention: Crizotinib; Not Applicable; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18999
Early Detection of Cancer Progression: Leveraging Team Science
Condition:
Intervention:
Open

CLINICAL TRIAL 18871
A Phase Ii, Open-Label, Multicenter, Single-Arm Study To Investigate TheEfficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage Ib, Ii, Iiia Or Selected Iiib Resectable And Untreated Non-Small Cell Lung Cancer
Condition:
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition:
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 18923
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Condition:
Intervention: BGB324; Erlotinib; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18811
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Condition:
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin
Open

CLINICAL TRIAL 19101
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); BMS-986205; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition:
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition:
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 19406
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nintedanib; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17969
Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition:
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 19339
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases
Condition:
Intervention: AZD9291 (Osimertinib); Avastin (Bevacizumab); Bevacizumab
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition:
Intervention: PBF-509; PDR001
Open

CLINICAL TRIAL 17361
A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Condition:
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 19077
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Condition:
Intervention: Paraplatin (carboplatin); carboplatin; cisplatin; etoposide
Open

CLINICAL TRIAL 19497
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Condition:
Intervention: MLN4924 (Pevonedistat); Paraplatin (carboplatin); Pevonedistat; Taxol (paclitaxel); Taxotere (docetaxel); carboplatin; docetaxel; paclitaxel
Open

CLINICAL TRIAL 19625
A Phase 1b Dose-Escalation Study Of TRC105 In Combination With Nivolumab In Patients With Metastatic Non-Small Cell Lung Cancer
Condition:
Intervention: BMS-936558 (Nivolumab); Carotuximab; Nivolumab; TRC105 (Carotuximab)
Open

CLINICAL TRIAL 19642
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Condition:
Intervention: ABT-263 (Navitoclax); AZD9291 (Osimertinib); Navitoclax
Open

CLINICAL TRIAL 19163
Combination Immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC) in patients with relapsed Small Cell Lung Cancer (SCLC)
Condition:
Intervention: Ad.p53 DC; BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors
Condition:
Intervention: BA3011
Open

CLINICAL TRIAL 19509
A Phase 1/2 Study Of Pegzilarginase (AEB1102, Co-Argi-PEG) In Combination With Pembrolizumab In The Treatment Of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Condition:
Intervention: Pegzilarginase; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19569
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)
Condition:
Intervention: AMP-514 (Durvalumab); BI 1361849; CP-675,206 (tremelimumab); Durvalumab; MEDI4736 (Durvalumab); tremelimumab
Open

CLINICAL TRIAL 19619
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition:
Intervention: AZD9291 (Osimertinib); G1T38; Osimertinib
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition:
Intervention: Not Applicable
Open

CLINICAL TRIAL 19656
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Condition:
Intervention: Ceritinib (Zykadia); Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 19387
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Condition:
Intervention: Poziotinib
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res. 2018 May;10:931-940. Pubmedid: 29760563. Pmcid: PMC5937504.
  • Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. CURR TREAT OPTION ON. 2018 Jun;19(8):39. Pubmedid: 29931587.
  • Shafique MR, Lee MC, Han HS. Treatment of the Pregnant Patient with Breast Cancer. South Med J. 2017 Oct;110(10):627-631. Pubmedid: 28973702.
  • Turza KC, Shafique M, Lobo PI, Sawyer RG, Keith DS, Brayman KL, Agarwal A. Infectious complications in living-donor kidney transplant recipients undergoing multi-modal desensitization. Surg Infect (Larchmt). 2014 Jun;15(3):182-186. Pubmedid: 24773230. Pmcid: PMC4696441.
  • Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Tr. 2014 Feb;20(2):257-263. Pubmedid: 24269380. Pmcid: PMC4140655.